Category: Biopharmaceutical

BridgeBio Pharma Secures $1.25 Billion to Propel Genetic Medicine Development

Introduction In a strategic move to accelerate the development and launch of genetic medicines, BridgeBio Pharma has successfully secured up to USD 1.25 billion from Blue Owl Capital and Canada Pension Plan Investment Board. The cornerstone of BridgeBio’s funding initiative involves a strategic agreement with Blue Owl Capital and Canada Pension Plan Investment Board. In

Biologics Contract Manufacturing: Changing Promise into Reality

Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. Further, with the advent of novel technologies, biologics have made a significant impact in the pharmaceutical domain, delivering ground-breaking treatment for a myriad of disease indications, including immunological, oncological and rare disorders. In this context,

Pharmaceutical Excipients – Current Scenario and Future Trends

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently

Pharmaceutical Excipient Market: Current Scenario and the Future

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical excipient products are

Biopharma CRO: Fueling the research of novel biologics

Biologics, often referred to as biopharmaceuticals or large molecules, are manufactured in the biological system, such as microorganisms, plants, or animal cells. Biologics contract manufacturing organizations represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapid pace of innovation in this field, driven by the need for

Fill Finish Services: Impact of the Growing Biopharma Pipelines

Biopharmaceuticals represent the most rapidly growing and high-value segment of the pharmaceutical industry. Growing at an annualized rate of ~10%, the biologics contract manufacturing market stands tall with more than 5,000 biologics in development and over 300 FDA approved biologics, since 2002. Biologic drug development is characterized by high quality standards and a rapidly growing

Biopharma Contract Manufacturing Market in China: Covid-19 Impact

China, epicenter of the COVID-19, is the world’s second largest pharmaceutical market and accounts for 20 % of the global output of APIs. With over 25 biologics and biosimilar products approved till date and close to 1,000 clinical trials, investigating a variety of biologics and biosimilars, being underway in this region, the biopharma contract manufacturing

CMO, CMO Everywhere, Not a Single One That Fits: The Reality of Biopharma Contract Manufacturing Market

I was recently involved in a discussion with the global outsourcing manager of one of the big pharma companies. The premise of the discussion was around the criteria that big Biopharma Contract players follow for choosing a supplier for their products. One key question that came up in the discussion was whether one-stop-shops are really

Biopharmaceutical CMO: The Growing Need

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Owing to the growing number of start-ups that are engaged in R&D of novel biologics, there is significant opportunity for the biopharmaceutical CMOs in this domain. It is worth highlighting that, since 2000, more than 115

Biopharma Contract Manufacturing: From Promise to Reality

The development and manufacturing processes opted by biologics CMO are complex, and usually require advanced capabilities and specialized expertise. This has led many stakeholders in the industry to outsource significant parts of their business operations to biopharma contract manufacturing service providers. The ‘Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017 – 2027’ report provides an extensive study of